Your browser doesn't support javascript.
loading
A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
Newton, C; Murali, K; Ahmad, A; Hockings, H; Graham, R; Liberale, V; Sarker, S-J; Ledermann, J; Berney, D M; Shamash, J; Banerjee, S; Stoneham, S; Lockley, M.
Afiliação
  • Newton C; Barts Health NHS Trust, West Smithfield, London, EC1A 7BE, UK; University College Hospital, 235 Euston Road London, NW1 2BU, UK; University Hospitals Bristol NHS Foundation Trust, Upper Maudlin Street, Bristol, BS2 8HW, UK; University of Bristol, Senate House, Tyndall Avenue, Bristol BS8 1TH, UK.
  • Murali K; The Royal Marsden Hospital, 203 Fulham Rd, Chelsea, London SW3 6JJ, UK.
  • Ahmad A; The Wolfson Institute, CRUK Barts Cancer Centre, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, UK; Cancer Intelligence, Cancer Research UK, Angel Building, 407 St John Street, London EC1V 4AD, UK.
  • Hockings H; Barts Health NHS Trust, West Smithfield, London, EC1A 7BE, UK; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
  • Graham R; University College Hospital, 235 Euston Road London, NW1 2BU, UK.
  • Liberale V; University College Hospital, 235 Euston Road London, NW1 2BU, UK.
  • Sarker SJ; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK; Research Department of Medical Education, UCL Medical School, Royal Free Campus, Hampstead, London NW3 2PR, UK.
  • Ledermann J; University College Hospital, 235 Euston Road London, NW1 2BU, UK.
  • Berney DM; Barts Health NHS Trust, West Smithfield, London, EC1A 7BE, UK; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
  • Shamash J; Barts Health NHS Trust, West Smithfield, London, EC1A 7BE, UK.
  • Banerjee S; The Royal Marsden Hospital, 203 Fulham Rd, Chelsea, London SW3 6JJ, UK.
  • Stoneham S; University College Hospital, 235 Euston Road London, NW1 2BU, UK.
  • Lockley M; Barts Health NHS Trust, West Smithfield, London, EC1A 7BE, UK; University College Hospital, 235 Euston Road London, NW1 2BU, UK; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: m.lockley@qmul.ac.uk.
Eur J Cancer ; 113: 19-27, 2019 05.
Article em En | MEDLINE | ID: mdl-30954883
ABSTRACT

BACKGROUND:

Adult guidelines recommend BEP (bleomycin, etoposide, cisplatin) for all ovarian germ cell tumours, causing debilitating toxicities in young patients who will survive long term. Paediatricians successfully reduce toxicities by using lower bleomycin doses and substituting carboplatin for cisplatin, while testicular and paediatric immature teratomas (ITs) are safely managed with surgery alone.

AIM:

The aim was to determine whether reduced-toxicity treatment could rationally be extended to patients older than 18 years.

METHODS:

Multicentre cohort study was carried out in four large UK cancer centres over 12 years.

RESULTS:

One hundred thirty-eight patients were enrolled. Overall survival was 93%, and event-free survival (EFS) was 72%. Neoadjuvant/adjuvant chemotherapy (82% BEP) caused 27 potentially chronic toxicities, and one patient subsequently died from acute lymphoblastic leukaemia. There was no difference in histology, stage or grade in patients ≤/>18 years, and EFS was not different in these age groups (≤1828% and >1828%; log-rank P = 0.96). Histological subtype powerfully predicted EFS (log-rank P = 4.9 × 10-7). Neoadjuvant/adjuvant chemotherapy reduced future relapse/progression in dysgerminoma (n = 37, chemo0% vs. no chemo20%), yolk sac tumour (n = 23, 26.3% vs.75%) and mixed germ cell tumour (n = 32, 40%vs.70%) but not in IT (n = 42, 33% vs.15%). Additionally, we observed no radiological responses to chemotherapy in ITs, pathological IT grade did not predict EFS (univariate hazard ratio 0.82, 95% confidence interval 0.57-1.19, P = 0.94) and there were no deaths in this subtype.

CONCLUSION:

Survival was excellent but chemotherapy toxicities were severe, implying significant overtreatment. Our data support the extension of reduced-toxicity, paediatric regimens to adults. Our practice-changing findings that IT was chemotherapy resistant and pathological grade uninformative strongly endorse exclusive surgical management of ovarian ITs at all ages.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Embrionárias de Células Germinativas Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur J Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Embrionárias de Células Germinativas Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur J Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido